Novartis underwent a corporate makeover in May when it split its pharmaceutical unit into two decisions, dedicating one exclusively for the development of cancer immunotherapy drugs. A spokesperson from the company said the folding of the cell and gene therapy division is an extension of this original reorganization.
“Most associates who were previously dedicated to cell and gene therapies will now be redeployed to areas where they will share their knowledge and improve execution of novel therapeutics in the immunotherapy space,” a Novartis spokesperson told Reuters.
Despite the changes, Novartis said it still plans to file a drug application next year for CTL019, a T-cell therapy intended to treat patients with acute lymphoblastic leukemia. The move will not affect the company’s focus on developing new drugs for hard-to-treat diseases through gene editing, according to the report.
More articles on supply chain:
Senators say Mylan’s discount program, generic EpiPen only temporary solution
Study: Pricey drug-coated stents don’t outperform conventional versions
Following inspection, Theranos withdraws FDA authorization request for Zika test
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.